9.26
price down icon1.59%   -0.15
after-market 시간 외 거래: 9.30 0.04 +0.43%
loading
전일 마감가:
$9.41
열려 있는:
$9.38
하루 거래량:
5.84M
Relative Volume:
0.45
시가총액:
$10.87B
수익:
$14.33B
순이익/손실:
$-3.79B
주가수익비율:
-2.9211
EPS:
-3.17
순현금흐름:
$1.84B
1주 성능:
+4.04%
1개월 성능:
+2.77%
6개월 성능:
-17.32%
1년 성능:
-23.34%
1일 변동 폭
Value
$9.22
$9.38
1주일 범위
Value
$8.895
$9.42
52주 변동 폭
Value
$6.85
$13.55

비아트리스 Stock (VTRS) Company Profile

Name
명칭
Viatris Inc
Name
전화
(724) 514-1465
Name
주소
1000 MYLAN BOULEVARD, CANONSBURG
Name
직원
32,000
Name
트위터
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
VTRS's Discussions on Twitter

VTRS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
VTRS
Viatris Inc
9.26 11.04B 14.33B -3.79B 1.84B -3.17
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
150.75 67.73B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.31 45.73B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.70 44.38B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.51 18.97B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
298.14 13.73B 2.99B 1.21B 1.13B 25.06

비아트리스 Stock (VTRS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-06 개시 Goldman Neutral
2024-07-19 재개 Jefferies Buy
2023-10-23 다운그레이드 BofA Securities Neutral → Underperform
2023-06-23 다운그레이드 Barclays Equal Weight → Underweight
2023-04-24 다운그레이드 Barclays Overweight → Equal Weight
2023-02-17 다운그레이드 BMO Capital Markets Outperform → Market Perform
2023-01-27 업그레이드 Jefferies Hold → Buy
2022-11-10 업그레이드 UBS Sell → Neutral
2022-11-08 업그레이드 Piper Sandler Underweight → Neutral
2022-10-21 재개 Jefferies Hold
2022-06-14 개시 UBS Sell
2022-05-10 다운그레이드 Piper Sandler Neutral → Underweight
2022-03-01 다운그레이드 BofA Securities Buy → Neutral
2022-03-01 다운그레이드 Raymond James Outperform → Mkt Perform
2021-06-15 개시 Citigroup Neutral
2021-04-07 재개 RBC Capital Mkts Outperform
2021-03-08 다운그레이드 Goldman Buy → Neutral
2021-03-02 다운그레이드 JP Morgan Overweight → Neutral
2021-02-26 다운그레이드 Wolfe Research Outperform → Peer Perform
2021-01-05 개시 Argus Hold
2020-12-14 개시 Bernstein Mkt Perform
모두보기

비아트리스 주식(VTRS)의 최신 뉴스

pulisher
01:38 AM

Neurovascular Guidewires Market Outlook 2025 to 2035: Growth - openPR.com

01:38 AM
pulisher
Jul 28, 2025

What data driven models say about Viatris Inc.’s futureDaily Market Momentum and Pressure Analysis - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

US Court Agrees To Throw Out Viatris Wegovy Infringement Case - insights.citeline.com

Jul 28, 2025
pulisher
Jul 28, 2025

How to interpret RSI for Viatris Inc. stockMomentum Stocks with Breakout Potential - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

Why Viatris Inc. stock attracts strong analyst attention Daily Trade Monitor with Pattern Alerts - Newser

Jul 28, 2025
pulisher
Jul 28, 2025

Why is Viatris Inc. stock attracting strong analyst attentionInvest in high-yield stocks with confidence - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How strong is Viatris Inc. company’s balance sheetAchieve rapid financial growth with expert help - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

How does Viatris Inc. compare to its industry peersFree Bull & Bear Market Updates - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How volatile is Viatris Inc. stock compared to the marketUnprecedented profit potential - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Why Viatris Inc. stock attracts strong analyst attentionSmart High Yield Swing Trades - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about Viatris Inc. stockTremendous wealth creation - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Viatris Inc. stock priceMarket-crushing profits - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What institutions are buying Viatris Inc. stock nowUnprecedented growth rates - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Bausch Health adds two pharmaceutical industry veterans to board By Investing.com - Investing.com Nigeria

Jul 24, 2025
pulisher
Jul 24, 2025

Bausch Health Expands Leadership: Ex-Viatris CEO and Bristol Myers Legal Chief Join Board in Strategic Move - Stock Titan

Jul 24, 2025
pulisher
Jul 24, 2025

Novo Nordisk defeated in Wegovy patent dispute by Viatris - Yahoo Finance

Jul 24, 2025
pulisher
Jul 23, 2025

Is Viatris Inc. a good long term investmentOutperformance with explosive growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Novo Nordisk loses Wegovy patent fight against generics maker Viatris - Endpoints News

Jul 23, 2025
pulisher
Jul 23, 2025

Viatris’ Wegovy Copy Sheds One Novo Patent in Delaware Lawsuit - Bloomberg Law News

Jul 23, 2025
pulisher
Jul 23, 2025

Covering The Flaws In The Viatris Undervaluation Argument (NASDAQ:VTRS) - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

What to Expect From Viatris' Next Quarterly Earnings Report - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

What To Expect From Viatris' Next Quarterly Earnings Report - Barchart.com

Jul 23, 2025
pulisher
Jul 22, 2025

VTRS Down on Late-Stage Study Failure of Eye Disease Drug - MSN

Jul 22, 2025
pulisher
Jul 21, 2025

Viatris down on late-stage trial setback for eye disorder therapy - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter

Jul 21, 2025
pulisher
Jul 20, 2025

Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Viatris Announces Disappointing Phase 3 Study Results for MR-139 in Blepharitis, But Continues to Focus on Delivering Novel Therapies. - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Trend Tracker for (VTRS) - news.stocktradersdaily.com

Jul 19, 2025
pulisher
Jul 19, 2025

Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest

Jul 19, 2025
pulisher
Jul 18, 2025

Viatris stock unchanged as Goldman maintains Neutral rating on trial miss By Investing.com - Investing.com South Africa

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review - Benzinga

Jul 18, 2025
pulisher
Jul 18, 2025

Why Viatris (VTRS) Stock Is Falling Today - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris stock unchanged as Goldman maintains Neutral rating on trial miss - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Shares Dip After Blepharitis Treatment Fails to Hit Main Study Goal - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target - Barron's

Jul 18, 2025
pulisher
Jul 18, 2025

Viatris' Resilience in Ophthalmology: Navigating Setbacks and Strategic Growth - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Why Is Viatris Stock Falling In Pre-market? - Nasdaq

Jul 18, 2025

비아트리스 (VTRS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_specialty_generic RDY
$14.70
price up icon 0.20%
$133.71
price up icon 1.19%
$298.14
price down icon 2.09%
$14.58
price down icon 2.28%
$72.41
price down icon 0.71%
자본화:     |  볼륨(24시간):